Brown, David R.
East, Honey E.
Eilerman, Bradley S.
Gordon, Murray B.
King, Elizabeth E.
Knecht, Laura A.
Salke, Brandon
Samson, Susan L.
Yuen, Kevin C. J.
Yau, Hanford
Funding for this research was provided by:
Corcept Therapeutics (Not applicable)
Article History
Received: 10 June 2020
Accepted: 1 September 2020
First Online: 29 October 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: D.R.B has been a consultant/advisor for Corcept and a speaker for Corcept, Merck, and Novo Nordisk.H.E.E. has been a consultant/advisor for Amgen and Corcept, a speaker for Amgen, BI/Lilly, and Corcept, and has received research support from Acasti and Corcept.B.S.E. has been a consultant/advisor for Corcept.M.B.G. has been a consultant/advisor for Corcept and Novo Nordisk, and has received research support from Camurus, Corcept, Crinetics, Ionis, Ipsen, Novartis, Novo Nordisk, Opko, Teva, and Strongbridge.E.E.K. has been a consultant/advisor and speaker for Corcept.L.A.K. has been a consultant/advisor for Corcept and a speaker for Corcept, Ipsen, and Strongbridge.B.S. reports that Optime Care, Inc. is the limited distribution contracted pharmacy for Corcept Therapeutics to dispense mifepristone.S.L.S. has received research support from Corcept and Novartis.K.C.J.Y. has been a consultant/advisor for Corcept, Novartis, and Strongbridge, and has received research support from Corcept, Crinetics, Millendo, and Novartis.H.Y. has been a consultant/advisor and a speaker for Corcept.All authors, except Dr. Salke, received a consulting fee from Corcept for participating in the Consensus Advisory Board in May 2019. Discussion during this event contributed to these consensus recommendations.